<DOC>
	<DOCNO>NCT00940563</DOCNO>
	<brief_summary>Open-label , multicenter study imatinib ( 400mg/die p.o . ) patient advance gastrointestinal stromal tumor . Patients treat 12 month . Data regard best clinical use term tumor response , survival , tolerability safety profile prospectively collect .</brief_summary>
	<brief_title>A Prospective , Multicenter Study Best Clinical Use Imatinib Advanced Gastrointestinal Stromal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients ≥ 18 year age . 2 . Histologically documented diagnosis GIST , unresectable and/or metastatic therefore incurable conventional multimodality approach . 3 . Immunohistochemical documentation ckit ( CD117 ) expression tumor , detect tumor sample take within 6 week study entry . 4 . At least one measurable site disease ( RECIST Criteria ) , response assessment criterion , appropriate . 5 . Performance status 0,1 , 2 3 ( ECOG ) . 6 . Adequate end organ function . 7 . Adequate bone marrow function . 8 . Female patient childbearing potential must negative pregnancy test within 7 day initiation study drug dosing . 1 . Previous treatment investigational agent within 28 day first day study drug dosing , unless disease rapidly progress . 2 . Other primary malignancy &lt; 5 year clinically assess disease free interval , except basal cell skin cancer , cervical carcinoma situ , neoplasms judge consultation Steering committee entail low risk relapse . 3 . Grade III/IV cardiac problem define New York Heart Association Criteria . 4 . Pregnancy , breastfeed . 5 . Severe and/or uncontrolled medical disease . 6 . Known brain metastasis . 7 . Known chronic liver disease ( i.e. , chronic active hepatitis , cirrhosis ) . 8 . Known diagnosis human immunodeficiency virus ( HIV ) infection . 9 . Previous treatment chemotherapy within 4 week ( 6 week nitrosoureas MitomycinC ) . 10 . Previous radiotherapy ≥ 25 % bone marrow . 11 . Major surgery within 2 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>GIST</keyword>
	<keyword>imatinib</keyword>
	<keyword>advanced GIST</keyword>
</DOC>